Kostya Chumakov discusses the hypothesis that oral poliovirus vaccine can provide non-specific protection against many other viruses, and might prevent infection with SARS-CoV-2.
Host: Vincent Racaniello
Guest: Kostya Chumakov
Click arrow to play
Download TWiV 604 (39 MB .mp3, 64 min)
Subscribe (free): iTunes, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- Nonpathogenic enteroviruses to prevent human disease (pdf) 6:13
- OPV for COVID-19 (pdf) 17:56
- Enteroviruses to prevent human infections (pdf) 7:08
- Image credit
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees.
Send your virology questions and comments to [email protected]
Great interview! Makes me hopeful.
Fascinating story about his family, would love to read a book about vaccine development centered around his family, especially Maria Voroshilova, can Carl Zimmer oder Sid Mukherjee write that, please? 🙂
That’s good enough: https://www.nytimes.com/2020/06/24/world/europe/vaccine-repurposing-polio-coronavirus.html?smid=tw-share
Prof. Chumakov mentioned that a large scale clinical trial showed that an OPV (Oral Polio Vaccine) reduced seasonal flu by 3.8 fold (~07:44 in the interview)?
How does that compare to the effectiveness vs IFV which ranges between 30-50% effective (depending on season and strain)? I’m starting to search through NCBI for papers relating to this. Any additional recommendations for research on the background of this fascinating finding?
And I hope the study into OPV as a possible prophylactic treatment against SARS2 will prove promising.